Innovative Use of Fostamatinib in Managing Refractory Immune Thrombocytopenia in an HIV-Positive Patient: A Case Report

Matteo Bellia; Riccardo Moia; Mattia Schipani; Carola Sella; Mariangela Greco; Wael Al Essa; Abdurraouf Mokhtar Mahmoud; Gianluca Gaidano; Andrea Patriarca

doi:10.1002/ccr3.70577

Innovative Use of Fostamatinib in Managing Refractory Immune Thrombocytopenia in an HIV-Positive Patient: A Case Report

Clin Case Rep. 2025 Jun 26;13(7):e70577. doi: 10.1002/ccr3.70577. eCollection 2025 Jul.

Authors

Matteo Bellia¹, Riccardo Moia¹, Mattia Schipani¹, Carola Sella¹, Mariangela Greco¹, Wael Al Essa¹, Abdurraouf Mokhtar Mahmoud¹, Gianluca Gaidano¹, Andrea Patriarca¹

Affiliation

¹ Division of Hematology, Department of Translational Medicine Universita' del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore Della Carità Novara Italy.

Abstract

Managing immune thrombocytopenia (ITP) in HIV patients remains challenging due to refractory cases and treatment limitations. This report highlights fostamatinib as a safe, effective, and antiretroviral therapy-compatible option, offering durable platelet stabilization in a difficult-to-treat population.

Keywords: ART; HIV infection; fostamatinib; immune thrombocytopenia.